224
Views
2
CrossRef citations to date
0
Altmetric
Omalizumab treatment in patients with severe chronic spontaneous urticaria: safety consideration from real-life experiences

Rapid, persistent, and simultaneous remission of urticaria and severe atopic dermatitis after treatment with omalizumab

, , , &
Pages 2-4 | Received 13 Apr 2018, Accepted 13 Nov 2018, Published online: 08 Jan 2019

References

  • Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014;69:3–16.
  • Leung D, Bieber T. Atopic dermatitis. Lancet. 2003;361:151–160.
  • Tezza G, Mazzei F, Boner A. Epigenetics of allergy. Early Hum Dev. 2013;89:S20–S21.
  • Gallo C, Vighi G, Schroeder J, et al. Chronic urticaria atopic dermatitis and celiac disease. Am J Gastroenterol. 1992;87:1684
  • Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. Autoimmun Rev. 2017;16:1196–1208.
  • Eichenfield L, Tom W, Chamlin S, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014; 70:338–351.
  • Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update. J Allergy Clin Immunol. 2013;131:295–299.
  • MacGlashan D, Bochner B, Adelman D, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1428–1445.
  • Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther. 2015;2015;9:4909–4915.
  • Vignola A, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: solar. Allergy. 2004;59:709–717.
  • Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allery. J Allergy Clin Immunol. 2004;133:360–361.
  • Bantz SK, Zhu Z, Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5:202.
  • Chen T, Chan S, Lack G, et al. The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan. Trials. 2017;23:18–231.
  • Fernández-Antón Martínez M, Leis-Dosil V, Alfageme-Roldán F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 2012;103:624–628.
  • Holm J, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.